Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP-PCI 2
NCT07361783Recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of heparin in ST elevation myocardial infarction (STEMI) (2 arms). Primary endpoints: Composite endpoint of all-cause death, recurrent myocardial infarction, urgent coronary revascularization, stent thrombosis, or stroke at 30 days and Major bleeding (BARC type 3~5) at 30 days. Started Jan 2026; status: recruiting.
02
Drugs
heparin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT07361783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361783.